Biotech Values

[DewDiligence]

All told, I think PTLA’s Betrixaban program is pretty close to being a scam. This opinion is based on:

• The phase-3 trial design (as discussed in prior posts in this thread);

• The spurious contention that Betrixaban is well-differentiated from Eliquis and Xarelto in the indication PTLA is pursing based on its PK profile; and

• Inflated numbers furnished by management about the size of the indication.

If not for the PRT-4445 antidote, I would consider PTLA a promising candidate for shorting.